- All sections
- C - Chemistrymetallurgy
- C07D - Heterocyclic compounds
- C07D 265/34 - 1,4-OxazinesHydrogenated 1,4-oxazines condensed with carbocyclic rings
Patent holdings for IPC class C07D 265/34
Total number of patents in this class: 109
10-year publication summary
|
4
|
8
|
3
|
9
|
7
|
6
|
9
|
4
|
6
|
1
|
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Merck Patent GmbH | 5723 |
9 |
| AbbVie Deutschland GmbH & Co. KG | 259 |
5 |
| VALO Health, Inc. | 184 |
5 |
| Oregon Health & Science University | 754 |
4 |
| Dana-Farber Cancer Institute, Inc. | 2629 |
3 |
| Neumedics | 5 |
3 |
| Teijin Pharma Limited | 253 |
3 |
| Vividion Therapeutics, Inc. | 40 |
3 |
| F. Hoffmann-La Roche AG | 7847 |
2 |
| Agency for Science, Technology and Research | 3684 |
2 |
| Fondazione Istituto Italiano di Tecnologia | 614 |
2 |
| Xenon Pharmaceuticals Inc. | 197 |
2 |
| Certa Therapeutics Pty. Ltd. | 18 |
2 |
| Wuhan Createrna Science and Technology Co.,Ltd. | 27 |
2 |
| Samsung Electronics Co., Ltd. | 152914 |
1 |
| Hoffmann-La Roche Inc. | 3659 |
1 |
| Samsung Display Co., Ltd. | 37602 |
1 |
| Merck Sharp & Dohme Corp. | 2185 |
1 |
| Pfizer Inc. | 3389 |
1 |
| Amgen Inc. | 4335 |
1 |
| Other owners | 56 |